Metabolomic analysis to detect urinary molecular changes associated with bipolar depression

Area of Science:

• Biochemistry
• Neuroscience
• Metabolomics

Background:

• Bipolar disorder (BD) is a severe mental health condition with diagnostic challenges, particularly its depressive episodes.
• Depressive episodes in BD are associated with high comorbidity and suicide risk, yet lack objective diagnostic biomarkers.
• Current diagnostic methods for bipolar depression rely on clinical observation, highlighting the need for objective markers.

Purpose of the Study:

• To identify potential urinary metabolite biomarkers for the diagnosis of bipolar depression.
• To investigate the metabolic pathways associated with bipolar depression using metabolomic profiling.
• To provide objective biochemical indicators for a more accurate diagnosis of bipolar depression.

Main Methods:

• Nuclear Magnetic Resonance (NMR) spectroscopy was employed to analyze urine samples from patients with bipolar depression (n=37) and healthy controls (n=48).
• Orthogonal Partial Least Square Discriminant Analysis (OPLS-DA) and t-tests were used for statistical analysis of the metabolomic data.
• MetaboAnalyst 3.0 was utilized to identify significantly altered metabolic pathways based on differential metabolite expression.

Main Results:

• Seven urinary metabolites were found to be significantly different between bipolar depression patients and healthy controls.
• Elevated levels of betaine, glycerol, hippuric acid, indole sulfate, trimethylamine oxide, and urea were observed in bipolar depression patients.
• A significantly lower level of inositol was detected in the urine of patients with bipolar depression compared to controls.

Conclusions:

• The identified differential metabolites, linked to lipid and gut microbiota metabolism, offer potential as objective biomarkers for bipolar depression.
• These findings provide crucial insights into the pathophysiology of bipolar depression, potentially improving diagnostic accuracy.
• The study establishes a foundation for future research and clinical applications of metabolomics in diagnosing and understanding bipolar depression.